Abbott推出DNA尿液检测诊断膀胱癌

 
 
一种以DNA为基础的尿液检测能够检测膀胱细胞的基因改变，其敏感度几乎是传统尿液细胞学检测的2倍，传统方法作为血尿患者的初始诊断检查。

UroVysion是由Abbott分子学(Des Plaines, IL, USA)公司开发的，使用DNA探针鉴别与膀胱癌相联系的4种染色体异常。UroVysion又叫做“分子细胞学”因为它能够同时检测传统细胞学的形态学细胞改变，以及分子DNA改变。

作为当前诊断方法的辅助手段，该技术既能够检测染色体病变，帮助临床医生监测既往诊断为膀胱癌患者的复发情况，同时可以作为疑似膀胱癌血尿患者的初始诊断检查。UroVysion是根据Abbott公司荧光原位杂交(FISH)技术而研发的，已经获得了美国食品药品管理局的批准。
 
DNA Urine Test Diagnoses Bladder Cancer
 
A DNA-based urine test that detects genetic changes in bladder cells has almost twice the sensitivity of conventional urine cytology tests for the initial diagnosis of bladder cancer in patients with hematuria (blood in urine).

UroVysion, which was developed by Abbott Molecular (Des Plaines, IL, USA), uses DNA probes to identify up to four chromosomal abnormalities frequently associated with bladder cancer. UroVysion is also known as “molecular cytology” because it assesses both morphologic cellular changes of conventional cytology and molecular DNA changes.

Intended as an aid to current diagnostic procedures, its ability to detect chromosomal change can provide deeper insight to the clinician in monitoring for tumor recurrence in patients previously diagnosed with bladder cancer, and in the initial diagnosis in patients with hematuria suspected of having bladder cancer. UroVysion is based on Abbott's proprietary fluorescence in situ hybridization (FISH) technology and has been approved by the U.S. Food and Drug Association (FDA).